RayThera

Executive Summary

RayThera is a Houston-based private biotechnology company focused on developing small molecule therapies for critical unmet needs in immunology. Founded in 2015, the company leverages decades of drug discovery expertise to accelerate development while maintaining rigorous standards. Although RayThera has not publicly disclosed its pipeline, stage of development, or funding history, its specialization in small molecule immunology positions it in a competitive and high-demand therapeutic area. The company's lack of disclosed catalysts or clinical milestones suggests it may be in early preclinical or research stages, requiring further validation through partnerships, financing, or regulatory progress. Given the limited public information, the conviction in near-term value creation is moderate, contingent on upcoming milestones.

Upcoming Catalysts (preview)

• Q4 2026Series A or B Financing Round60% success
• H1 2027Lead Program IND Filing40% success
• Q2 2027Research Partnership or Licensing Deal50% success